{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:59:54Z","timestamp":1790945994281,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"University of Antwerp Research Fund"},{"name":"Janssen Pharmaceutica NV and ADx Neurosciences"},{"name":"Institute Born-Bunge, Antwerp"},{"name":"ZonMW-Memorabel","award":["733050206"],"award-info":[{"award-number":["733050206"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Alzheimer\u2019s disease CSF biomarkers 42 amino acid long amyloid-\u03b2 peptide (A\u03b21\u201342), total tau protein (T-tau), and tau protein phosphorylated at threonine 181 (P-tau181) are considered surrogate biomarkers of Alzheimer\u2019s disease pathology, and significantly improve diagnostic accuracy. Their ability to reflect neuropathological changes later in the disease course is not well characterized. This study aimed to assess the potential of CSF biomarkers measured in mid to late stage Alzheimer\u2019s disease to reflect post-mortem neuropathological changes. Individuals were selected from two autopsy cohorts of Alzheimer\u2019s disease patients in Antwerp and Amsterdam. Neuropathological diagnosis was performed according to the updated consensus National Institute on Aging-Alzheimer\u2019s Association guidelines, which includes quantification of amyloid-\u03b2 plaque, neurofibrillary tangle, and neuritic plaque load. CSF samples were analysed for A\u03b21\u201342, T-tau, and P-tau181 by ELISA. One hundred and fourteen cases of pure definite Alzheimer\u2019s disease were included in the study (mean age 74 years, disease duration 6 years at CSF sampling, 50% females). Median interval between CSF sampling and death was 1 year. We found no association between A\u03b21\u201342 and Alzheimer\u2019s disease neuropathological change profile. In contrast, an association of P-tau181 and T-tau with Alzheimer\u2019s disease neuropathological change profile was observed. P-tau181 was associated with all three individual Montine scores, and the associations became stronger and more significant as the interval between lumbar puncture and death increased. T-tau was also associated with all three Montine scores, but in individuals with longer intervals from lumbar puncture to death only. Stratification of the cohort according to APOE \u03b54 carrier status revealed that the associations applied mostly to APOE \u03b54 non-carriers. Our data suggest that similar to what has been reported for A\u03b21\u201342, plateau levels of P-tau181 and T-tau are reached during the disease course, albeit at later disease stages, reducing the potential of tau biomarkers to monitor Alzheimer\u2019s disease pathology as the disease progresses. As a consequence, CSF biomarkers, which are performant for clinical diagnosis of early Alzheimer\u2019s disease, may not be well suited for staging or monitoring Alzheimer\u2019s disease pathology as it progresses through later stages.<\/jats:p>","DOI":"10.1093\/brain\/awac013","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T20:13:48Z","timestamp":1641932028000},"page":"4056-4064","source":"Crossref","is-referenced-by-count":42,"title":["Associating Alzheimer\u2019s disease pathology with its cerebrospinal fluid biomarkers"],"prefix":"10.1093","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7267-7676","authenticated-orcid":false,"given":"Claire","family":"Bridel","sequence":"first","affiliation":[{"name":"Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands"},{"name":"Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospital , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charisse","family":"Somers","sequence":"additional","affiliation":[{"name":"Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sieben","sequence":"additional","affiliation":[{"name":"Biobank, Institute Born-Bunge, University of Antwerp , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Rozemuller","sequence":"additional","affiliation":[{"name":"Department of Pathology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Niemantsverdriet","sequence":"additional","affiliation":[{"name":"Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Struyfs","sequence":"additional","affiliation":[{"name":"Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Vermeiren","sequence":"additional","affiliation":[{"name":"Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp , Antwerp , Belgium"},{"name":"Chair Group of Nutritional Biology, Division of Human Nutrition and Health, Wageningen University and Research (WUR) , Wageningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Van Broeckhoven","sequence":"additional","affiliation":[{"name":"Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB , Antwerp , Belgium"},{"name":"Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P","family":"De Deyn","sequence":"additional","affiliation":[{"name":"Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp , Antwerp , Belgium"},{"name":"Biobank, Institute Born-Bunge, University of Antwerp , Antwerp , Belgium"},{"name":"Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bjerke","sequence":"additional","affiliation":[{"name":"Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp , Antwerp , Belgium"},{"name":"Vrije Universiteit Brussel, Center for Neurosciences (C4N) , Brussels , Belgium"},{"name":"Universitair Ziekenhuis Brussel, Laboratory of Neurochemistry , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Nagels","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Brussel, Center for Neurosciences (C4N) , Brussels , Belgium"},{"name":"Department of Neurology, Universitair Ziekenhuis Brussel , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Engelborghs","sequence":"additional","affiliation":[{"name":"Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp , Antwerp , Belgium"},{"name":"Vrije Universiteit Brussel, Center for Neurosciences (C4N) , Brussels , Belgium"},{"name":"Department of Neurology, Universitair Ziekenhuis Brussel , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"issue":"1","key":"2022112205312569000_awac013-B1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3233\/JAD-151097","article-title":"A decade of cerebrospinal fluid biomarkers for Alzheimer\u2019s disease in Belgium","volume":"54","author":"Somers","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"15","key":"2022112205312569000_awac013-B2","first-page":"1","article-title":"Seminar Alzheimer\u2019s disease","volume":"6736","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"2022112205312569000_awac013-B3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/nm.2221","article-title":"Biomarkers in Alzheimer\u2019s disease drug development","volume":"16","author":"Blennow","year":"2010","journal-title":"Nat Med"},{"issue":"1","key":"2022112205312569000_awac013-B4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"issue":"8","key":"2022112205312569000_awac013-B5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.neurobiolaging.2007.02.016","article-title":"Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia","volume":"29","author":"Engelborghs","year":"2008","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2022112205312569000_awac013-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"12","key":"2022112205312569000_awac013-B7","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"issue":"4","key":"2022112205312569000_awac013-B8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2022112205312569000_awac013-B9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol"},{"key":"2022112205312569000_awac013-B10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","article-title":"The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease","volume":"41","author":"Mirra","year":"1991","journal-title":"Neurology"},{"issue":"4","key":"2022112205312569000_awac013-B11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","article-title":"CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study","volume":"60","author":"Strozyk","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"2022112205312569000_awac013-B12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurol.2008.596","article-title":"Cerebrospinal fluid \u03b2-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain","volume":"66","author":"Tapiola","year":"2009","journal-title":"Arch Neurol"},{"issue":"9","key":"2022112205312569000_awac013-B13","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1093\/brain\/awm136","article-title":"No association of CSF biomarkers with APOE 4, plaque and tangle burden in definite Alzheimer\u2019s disease","volume":"130","author":"Engelborghs","year":"2007","journal-title":"Brain"},{"issue":"11","key":"2022112205312569000_awac013-B14","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"issue":"1","key":"2022112205312569000_awac013-B15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"2022112205312569000_awac013-B16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00401-016-1537-1","article-title":"Updated TDP-43 in Alzheimer\u2019s disease staging scheme","volume":"131","author":"Josephs","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2022112205312569000_awac013-B17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00401-011-0845-8","article-title":"A harmonized classification system for FTLD-TDP pathology","volume":"122","author":"Mackenzie","year":"2011","journal-title":"Acta Neuropathol"},{"issue":"14","key":"2022112205312569000_awac013-B18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1212\/WNL.0b013e31824e8e7f","article-title":"Staging and natural history of cerebrovascular pathology in dementia","volume":"78","author":"Kalaria","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"2022112205312569000_awac013-B19","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/brain\/aww214","article-title":"Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment","volume":"139","author":"Skrobot","year":"2016","journal-title":"Brain"},{"key":"2022112205312569000_awac013-B20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","article-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases","volume":"8","author":"Engelborghs","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"2022112205312569000_awac013-B21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3233\/JAD-140405","article-title":"Depression in mild cognitive impairment is associated with progression to Alzheimer\u2019s disease: a longitudinal study","volume":"42","author":"Van der Mussele","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"2022112205312569000_awac013-B22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","article-title":"Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-\u03b2 1\u201342 analysis results","volume":"64","author":"Tijms","year":"2018","journal-title":"Clin Chem"},{"issue":"4","key":"2022112205312569000_awac013-B23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2022112205312569000_awac013-B24","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.55.7.964","article-title":"Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam study","volume":"55","author":"Slooter","year":"1998","journal-title":"Arch Neurol"},{"issue":"1","key":"2022112205312569000_awac013-B25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/JAD-132306","article-title":"Optimizing patient care and research: the Amsterdam Dementia Cohort","volume":"41","author":"van der Flier","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"2022112205312569000_awac013-B26","doi-asserted-by":"crossref","first-page":"e11170","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"226","key":"2022112205312569000_awac013-B27","doi-asserted-by":"crossref","first-page":"226ra30","DOI":"10.1126\/scitranslmed.3007901","article-title":"Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer\u2019s disease","volume":"6","author":"Fagan","year":"2014","journal-title":"Sci Transl Med"},{"issue":"2","key":"2022112205312569000_awac013-B28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ana.21694","article-title":"Cerebrospinal fluid amyloid \u03b240 is decreased in cerebral amyloid angiopathy","volume":"66","author":"Verbeek","year":"2009","journal-title":"Ann Neurol"},{"issue":"11","key":"2022112205312569000_awac013-B29","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s00415-012-6520-8","article-title":"Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria","volume":"259","author":"Renard","year":"2012","journal-title":"J Neurol"},{"issue":"2","key":"2022112205312569000_awac013-B30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.0000000000003486","article-title":"\u03b2-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy","volume":"88","author":"van Etten","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"2022112205312569000_awac013-B31","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1074\/jbc.270.2.823","article-title":"Proline-directed and non-proline-directed phosphorylation of PHF-tau","volume":"270","author":"Morishima-Kawashima","year":"1995","journal-title":"J Biol Chem"},{"issue":"32","key":"2022112205312569000_awac013-B32","doi-asserted-by":"crossref","first-page":"23645","DOI":"10.1074\/jbc.M703269200","article-title":"Novel Phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis","volume":"282","author":"Hanger","year":"2007","journal-title":"J Biol Chem"},{"issue":"6","key":"2022112205312569000_awac013-B33","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.cell.2020.10.029","article-title":"Tau PTM profiles identify patient heterogeneity and stages of Alzheimer\u2019s disease","volume":"183","author":"Wesseling","year":"2020","journal-title":"Cell"},{"issue":"5","key":"2022112205312569000_awac013-B34","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1212\/WNL.0000000000004887","article-title":"Comparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease","volume":"90","author":"Mattsson","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"2022112205312569000_awac013-B35","first-page":"275","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathologye","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA Neurol"},{"issue":"6","key":"2022112205312569000_awac013-B36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jalz.2019.02.005","article-title":"Comparison of 18F-florbetaben quantification results using the standard centiloid, MR-based, and MR-less CapAIBL\u00ae approaches: validation against histopathology","volume":"15","author":"Dor\u00e9","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2022112205312569000_awac013-B37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.dadm.2017.06.001","article-title":"Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer\u2019s disease","volume":"9","author":"Salloway","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"issue":"8","key":"2022112205312569000_awac013-B38","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/brain\/aww139","article-title":"The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging","volume":"139","author":"Gordon","year":"2016","journal-title":"Brain"},{"issue":"5","key":"2022112205312569000_awac013-B39","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","article-title":"Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2022112205312569000_awac013-B40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ana.410380120","article-title":"Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer\u2019s disease","volume":"38","author":"Sorbi","year":"1995","journal-title":"Ann Neurol"},{"issue":"2","key":"2022112205312569000_awac013-B41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ana.10636","article-title":"Apolipoprotein E\u03b54 modifies Alzheimer\u2019s disease onset in an E280A PS1 kindred","volume":"54","author":"Pastor","year":"2003","journal-title":"Ann Neurol"},{"issue":"1","key":"2022112205312569000_awac013-B42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajmg.b.30087","article-title":"APOE and other loci affect age-at-onset in Alzheimer\u2019s disease families with PS2 mutation","volume":"132B","author":"Wijsman","year":"2005","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2022112205312569000_awac013-B43","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/mp.2017.204","article-title":"Blood-derived amyloid-\u03b2 protein induces Alzheimer\u2019s disease pathologies","volume":"23","author":"Bu","year":"2018","journal-title":"Mol Psychiatry"},{"issue":"5","key":"2022112205312569000_awac013-B44","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2017.11.022","article-title":"Seeds of destruction: new mechanistic insights into the role of apolipoprotein E4 in Alzheimer\u2019s disease","volume":"96","author":"Vassar","year":"2017","journal-title":"Neuron"},{"issue":"3","key":"2022112205312569000_awac013-B45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the national Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awac013\/45485656\/awac013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/145\/11\/4056\/47175048\/awac013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/145\/11\/4056\/47175048\/awac013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T05:33:42Z","timestamp":1669095222000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/145\/11\/4056\/6506576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,1,13]]},"published-print":{"date-parts":[[2022,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awac013","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,1,13]]}}}